SCHEMBL334919

SCHEMBL334919

O=C(O)Cc1cc(O)cc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 1/20 0.50
CA2 P00918 2/20 0.48
CAMK2A Q9UQM7 2/20 0.48
THRB P10828 6/20 0.47
THRA P10827 5/20 0.47
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 1/20 0.44
RGS12 O14924 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
APEX1 P27695 1/20 0.44
THPO P40225 1/20 0.44
BLM P54132 1/20 0.44
GNAI1 P63096 1/20 0.44
PMP22 Q01453 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21273844 0.87 CA2 (0.50) CA2CAMK2ATHRBTHRAMAPT
SCHEMBL868125 0.87 CA2 (0.50) CA2CAMK2ATHRBTHRAMAPT
SCHEMBL477986 0.84 CA2 (0.58) CA2CAMK2ATHRBTHRAMAPT
SCHEMBL1651345 0.82 CA2 (0.50) HCAR1CA2MAPTHPGDHSP90AB1
SCHEMBL156863 0.78 FFAR4 (0.43) CA2THRBTHRAMAPTHPGD
SCHEMBL586651 0.78 CA2 (0.43) CA2CAMK2ATHRBTHRAMAPT
SCHEMBL1244868 0.78 THRB (0.43) CA2CAMK2ATHRBTHRAMAPT
SCHEMBL137705 0.78 THRB (0.47) CA2THRBTHRAMAPTHPGD
SCHEMBL1246654 0.78 THRB (0.43) CA2THRBTHRAMAPTHPGD
SCHEMBL27809773 0.78 CA2 (0.43) CA2CAMK2ATHRBTHRAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101326161-B Novel compounds ASTRAZENECA AB 2013-04-17 CN disclosed
EP-1585511-B1 ASTHMA AND ALLERGIC INFLAMMATION MODULATORS AMGEN INC (US) 2013-01-23 EP disclosed
EP-1585511-B1 ASTHMA AND ALLERGIC INFLAMMATION MODULATORS AMGEN INC (US) 2013-01-23 EP disclosed
US-8148572-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 US disclosed
EP-1963259-B1 SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2012-02-15 EP disclosed
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
EP-2305640-A2 Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases AstraZeneca AB (SE) 2011-04-06 EP disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
US-20090192163-A1 Novel Compounds ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-7541383-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2009-06-02 US disclosed
US-20080085891-A1 Asthma and allergic inflammation modulators FU ZICE 2008-04-10 US disclosed
US-7321001-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2008-01-22 US disclosed
US-7321001-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2008-01-22 US disclosed
US-7321001-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2008-01-22 US disclosed
EP-1585511-A4 ASTHMA AND ALLERGIC INFLAMMATION MODULATORS AMGEN INC (US) 2007-08-29 EP disclosed
WO-2007068894-A2 SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2007-06-21 WO disclosed
CN-1767823-A Asthma and allergic inflammation modulators AMGEN INC (US) 2006-05-03 CN disclosed
EP-1585511-A2 ASTHMA AND ALLERGIC INFLAMMATION MODULATORS Tularik, Inc. (US) 2005-10-19 EP disclosed
US-20040220237-A1 Asthma and allergic inflammation modulators AMGEN INC. 2004-11-04 US disclosed
WO-2004058164-A2 ASTHMA AND ALLERGIC INFLAMMATION MODULATORS TULARIK, INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085891-A1 Asthma and allergic inflammation modulators IL5, TSLP, CYSLTR2 HCAR1 20/4885CA2 523/4885CAMK2A 1091/4885
US-20090286974-A1 Derivative having ppar agonistic activity PPARD, PPARA, PPARG HCAR1 351/4885CA2 4009/4885CAMK2A 3266/4885
US-20040220237-A1 Asthma and allergic inflammation modulators IL5, TSLP, CYSLTR2 HCAR1 20/4885CA2 523/4885CAMK2A 1091/4885
US-20090192163-A1 Novel Compounds PAH, PC, DDC HCAR1 21/4885CA2 513/4885CAMK2A 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.